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Abstract
Background: BRENDA (BRaunschweig ENzyme DAtabase, http://www.brenda-enzymes.org) is a major resource for
enzyme related information. First and foremost, it provides data which are manually curated from the primary
literature. DRENDA (Disease RElated ENzyme information DAtabase) complements BRENDA with a focus on the
automatic search and categorization of enzyme and disease related information from title and abstracts of primary
publications. In a two-step procedure DRENDA makes use of text mining and machine learning methods.
Results: Currently enzyme and disease related references are biannually updated as part of the standard BRENDA
update. 910,897 relations of EC-numbers and diseases were extracted from titles or abstracts and are included in
the second release in 2010. The enzyme and disease entity recognition has been successfully enhanced by a
further relation classification via machine learning. The classification step has been evaluated by a 5-fold cross
validation and achieves an F1 score between 0.802 ± 0.032 and 0.738 ± 0.033 depending on the categories and
pre-processing procedures. In the eventual DRENDA content every category reaches a classification specificity of at
least 96.7% and a precision that ranges from 86-98% in the highest confidence level, and 64-83% for the smallest
confidence level associated with higher recall.
Conclusions: The DRENDA processing chain analyses PubMed, locates references with disease-related information
on enzymes and categorises their focus according to the categories causal interaction, therapeutic application,
diagnostic usage and ongoing research. The categorisation gives an impression on the focus of the located
references. Thus, the relation categorisation can facilitate orientation within the rapidly growing number of
references with impact on diseases and enzymes. The DRENDA information is available as additional information in
BRENDA.
Background
Automatic bio-entity recognition and bio-entity relation
classification has found a number of applications in the
recent years [1,2]. On the one hand the work of manual
expert information extraction is time-consuming and
expensive and on the other hand computational power
gets cheaper and the growth of publications in the bio-
medical field is tremendous. Thus applications in this
area quickly gain more importance.
Some disease-related approaches concentrate on a
rather precisely defined problem like the extraction of
human kinase mutations [3]. The EnzyMiner routine [4]
identifies PubMed abstracts that contain information on
a mutation for an enzyme and tries to connect it to a
disease. On the EnzyMiner website http://bioapps.saban-
ciuniv.edu/enzyminer/ disease and non-disease con-
nected information on a very small number of enzymes
(22) is available, mutation information on further
enzymes has to be requested by an email form. Other
information resources present information on all genes
and proteins, their physical interactions and regulatory
relationships like iHOP [5]http://www.ihop-net.org/Uni-
Pub/iHOP/ where information on enzymes and diseases
c a nb ef o u n db u ti sn o ti nt h ev e r yf o c u s .M e d E v i[ 6 ]
http://www.ebi.ac.uk/Rebholz-srv/MedEvi/ is available
through web-access as well and presents references and
the particular evidence-sentence containing biomedical
entities and semantic relations that are requested
through a multi-term query.
For a number of years now the AMENDA and
FRENDA databases are provided as a supplement to the
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are extracted from literature abstracts using text-mining
procedures.
Here we describe the development and contents of
DRENDA, which is developed to complement the
BRENDA knowledge system with information on dis-
eases related to enzymes. BRENDA currently contains
about 3 million qualitative and quantitative data on
4,624 active EC-numbers manually extracted from more
than 100,000 references. The data cover multiple aspects
associated with a descriptive view on enzymes such as
classification and nomenclature, reaction and specificity,
functional parameters, occurrence, enzyme structure,
application, mutant information and engineered variants,
stability, isolation and preparation. Although the num-
ber of annotated references increased by 30% since 2009
it is impossible to manually annotate all published refer-
ences containing relevant information on enzymes.
However, as the techniques and means of text mining
and machine learning are improving it is possible to
present automatically gained information, satisfying in
quality and quantity.
The DRENDA text mining routine retrieves enzyme-
related information on diseases in PubMed [8] by locat-
ing the incidence of enzymes and diseases in the litera-
ture. Enzymes represent the largest and most diverse
group of all proteins. Due to their dominating role in
metabolism and regulation, the malfunction of enzymes
almost always leads to pathological processes in the
organism. DRENDA provides information on the role of
enzymes in diseases. Moreover all data are connected to
a reference. A further classification of the enzyme role,
e.g. the pharmacological or diagnostic value of an
enzyme or its malfunction, is described in this paper.
The assignment of statements within a reference into
the four categories causal interaction, ongoing research,
therapeutic application and diagnostic usage allows to
identify interesting biomedical aspects in the scientific
literature of high information value. The categories were
chosen so that it is quickly possible to get information
on the role of enzymes in the context of diseases.
The Fabry disease is an inherited disorder of glyco-
sphingolipid metabolism due to a deficiency of the
enzyme alpha-galactosidase (EC 3.2.1.22), being an
example for a causal interaction between an enzyme
and a disease. The statement “...a disease-specific thera-
peutic option - enzyme replacement therapy using recom-
binant human alpha-galactosidase has been recently
introduced...” [9] describes the therapeutic application in
which the enzyme is the drug itself for the treatment of
the disease.
More frequently the enzyme is used as the drug target
as, for example, in therapeutic strategies that focus on
the inhibition of enzymes of pathogenic viruses and
bacteria. The title “The HIV-1 protease as a therapeutic
target for AIDS” [10] is easily assigned to the category
therapeutic application.
The title “Serum Alkaline Phosphatase Level as a
Prognostic Tool in Colorectal Cancer...” [11] is an exam-
ple for the assignment to the category diagnostic usage.
The finding of abnormal activity of the isoenzymes
(bone, liver) may indicate a broad range of pathological
conditions like cirrhosis, hepatitis, liver tumours, drug
intoxication, renal diseases, bone diseases and the pre-
sence of metastases.
The category ongoing research comprises references
that contain statements indicating a preliminary relation
between enzyme and disease but more research effort is
necessary, e.g. indicated in the reference title “N-acetyl-
galactosaminyl transferase-3 is a potential new marker
for non-small cell lung cancers.” [12].
This publication focuses on the development and con-
tent of DRENDA which provides information on dis-
eases and enzymes and their categorised relations.
Methods
Workflow and auxiliary means
The DRENDA work flow is based on the disease mining
procedures already included in BRENDA [13] but
strongly enhanced inter alia by the added classification
feature. The work flow (Figure 1) is implemented in
Python and uses MySQL as database back-end. The first
step is the initial sentence splitting (Figure 1, Sentence
splitting) and search for the co-occurrence of enzyme
and disease terms (Figure 1, Co-occurrence matching)
within the title or an abstract sentence of the references
enlisted in PubMed. The BRENDA enzyme names and
Figure 1 A schematic illustration of the DRENDA work flow.
The BRENDA enzyme names and synonyms and the MeSH disease
terms are used as dictionaries. The PubMed abstracts and titles are
searched for co-occurring disease and enzyme entities. A test/train
corpus was created for training an SVM and classifying the co-
occurrence results according to the categories causal interaction,
therapeutic application, diagnostic usage and ongoing research. The
resulting entries are stored in the DRENDA database.
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comprise currently around 100,000 terms. This collec-
tion is certainly the largest available reference dictionary
for the identification of enzyme entities (Figure 1,
BRENDA).
The terms for disease recognition are taken from the
Medical Subject Headings (MeSH) [14]. The selected
disease terms are a subset containing about 22,000 dis-
ease names and synonyms (Figure 1, MeSH). The titles
and sentences, where at least one co-occurring enzyme
and disease entity could be found (Figure 1, Result set
co-occurrence) are the basis of the DRENDA content
and stored as corpus for the subsequent classification.
Relation classification
The classification is accomplished by machine learning
methods. The basic classification unit is a sentence or
title from PubMed abstracts where at least one enzyme
and disease entity could be found (Figure 1, Result set
co-occurrence). As they contain only a small number of
words the problem is characterised by a sparse feature
representation and offers the possibility to perform the
classification via a Support Vector Machine (SVM) that
have proven to perform well on text classification tasks
[15]. We have used SVMlight [16] as SVM implementa-
tion. In order to use an SVM for classification the avail-
ability of training and testing material is an essential
requirement. For this purpose a corpus has been com-
posed (Figure 1, Test corpus; Train corpus), which con-
tains about 5,031 sentences and titles derived from
PubMed abstracts. The selection out of all sentences
and titles was made accordingly the following condi-
tions: 2,500 have been randomly selected where at least
one enzyme entity was identified. 2,000 have been ran-
domly selected where at least one enzyme entity and
one disease entity was identified. About 500 were ran-
domly collected without any precondition from PubMed
abstracts and titles. This corpus was manually annotated
by an expert with biomedical background, for the identi-
fication of the presence of enzyme and disease entities
and the assignment of all categories. If both entities are
present within one sentence or title the relation was
manually classified into the four categories of causal
interaction, therapeutic application, diagnostic usage and
ongoing research. In addition to the deployment as train-
ing and test data it is also used to evaluate the co-occur-
rence matches (Figure 1, Evaluation).
Classification categories
Causal interaction
The crucial role of enzymes in catalysing metabolic
reactions in organisms implies that malfunction, directly
caused by a mutation in the coding gene or indirectly
b yt h ep r e s e n c eo fi n h i b i t o r s( e . g .s i d ee f f e c t so fd r u g s )
or the absence of required cofactors, most often induces
pathological conditions. The category causal interaction
comprises references which describe such a relation
between an enzyme and disease entity. The training/test
corpus contains 1,382 sentences/titles which are anno-
tated for the class causal interaction.
Example sentence for this category:
„Chronic granulomatous disease (CGD) results from
mutations of phagocyte NADPH oxidase.“ [17]
Ongoing research
In a large number of publications a distinct interrelation
of enzymatic function and the development or progress
o fad i s e a s ei sp r e s u m e db u tn o ty e tf u l l yp r o v e na n d
further research investigation is needed. This instance
describes the category ongoing research. 587 sentences
of the training/test corpus are assigned to this category.
Example sentence for this category:
„The prognostic significance of epidermal growth fac-
tor receptor (EGFR) expression in lung cancer and,
more importantly, its ability to predict response to
anti-EGFR therapies, are currently subjects of active
research.“ [18]
Diagnostic usage
In a clinical laboratory a multitude of parameters are
examined for clarifying the presence of a pathological
state or its severity. Many of these methods are based
on the measurement of enzyme activities in the
specimen.
Gamma-glutamyltransferase (EC 2.3.2.2) for instance,
catalyses the transfer of a glutamyl residue from glu-
tathione to an acceptor amino acid and its change in
activity is used e.g. as an indicator of a liver dysfunction
[19] which may be caused by excessive alcohol con-
sumption. If an author states that an examination of an
enzyme like the measurement of its activity, the test for
its presence or the assay of its functional characteristic
parameters are part of the diagnostic course of action,
this reference is considered as included within the
DRENDA category diagnostic usage. In the annotated
training/test corpus 477 sentences/titles are in this
category.
Example sentence for this category:
„Prostate-specific antigen (PSA) is the most clinically
useful tumour marker available today for the diagno-
sis and management of prostate cancer.“ [20]
Therapeutic application
Given that enzymes play a major role in the develop-
ment and progress of many diseases, they are also of
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one hand enzymes are considered as targets for drugs,
on the other hand the enzyme itself may be the drug. If
the enzyme is either a drug target or the drug agent for
a mentioned disease, the corresponding reference is allo-
cated to the category therapeutic application. The train-
ing/test corpus contains 366 sentences/titles
corresponding to this category, about 62% of these sen-
tences/titles describe cases where the enzyme is a drug
target during the therapeutic intervention against the
disease.
Example sentence for this category:
„Indinavir sulfate is a human immunodeficiency
virus type 1 (HIV-1) protease inhibitor indicated for
treatment of HIV infection and AIDS in adults.“ [21]
Preprocessing and representation
In order to form a suitable input for SVM classification
the set of titles and sentences, which were classified to
contain a co-occurrence of an enzyme and disease, are
prepared in a preprocessing step (Figure 1,
Preprocessing).
First, terms that represent the entities “enzyme” and
“disease” are removed (removal)o rr e p l a c e d( replace-
ment) by a general term representing all enzyme
respectively disease terms. This means that in the
removal method all terms are deleted which are known
to represent names and synonyms of enzymes or dis-
eases without any substitution. In the replacement
method the deleted names are replaced by a single
generic term for all diseases and one generic term for
all enzymes. Given that these two generic terms not
have been present in the sentences and titles of the
result set co-occurrence before their insertion during
the preprocessing process.
The titles and sentences are represented as feature
vectors within a document space [22]. The feature vec-
tor representation of a sentence or a title is performed
via a calculation of the term frequency inverse docu-
ment frequency tf-idf. The term frequency tfij is the
number of occurrences of the term ti in the particular
sentences or title dj. The inverse document frequency
idfi is calculated as
idfi =l n

D
1+dit

(1)
where D is the overall number of sentences and titles
and dit is the number of sentences and titles containing
ti. tf-idf is the product of tfij and idfi.
tf - idf = tfij ∗ idfi (2)
Finally, all coordinates are divided by the length of the
feature vector. Thereby each feature vector is converted
to unit vector length, neutralizing the influence of the
different sentence lengths.
Classification of the co-occurrence results
As the next step of the described DRENDA work flow a
classification of the co-occurrence results is performed.
The test/training corpus has been randomly split into 4/
5 training examples and 1/5 test examples. Every dis-
crete classification category contains the same quantity
of positive and negative annotated sentences/titles. The
overall number of examples differs between each classi-
fication category due to the amount of positive assigned
sentences/titles in each category. All sentences/titles
which were positively annotated for one category are
joined with the same amount of sentences/titles, nega-
tively annotated for this category and containing at least
one co-occurrence of an enzyme and disease entity.
A classification model (Figure 1, SVM training) is cal-
culated and used to perform the classification of co-
occurrence results (Figure 1, SVM classification). The
classification results are finally distributed into a four
level confidence system with descending classification
precision and specificity from level 4 to 1.
Cross validation
Before establishing the described DRENDA work flow
( F i g u r e1 )af i v e - f o l dc r o s s - v alidation was performed to
test the performance of the preprocessing steps and
methods (removal; replacement) and the appropriate
parameter choice for SVMlight. The overall ability of
classification and assignment of sentences to the prede-
fined categories was validated. In every category, causal
interaction, therapeutic application, diagnostic usage and
ongoing research, the same quantity of positive and
negative annotated sentences/titles was chosen out of
the training/test corpus and split randomly into five sets
of equal size. Each individual set served once as a testing
set while the other four formed a training set. Several
calibrations of SVMlight parameters were tested as well
as all four default kernel functions implemented in
SVMlight (linear, polynomial, radial basis, sigmoid) were
tested. This led to 2,688 distinct parameter combina-
tions processed for each preprocessing method, removal
and replacement. The classification of the co-occurrence
results in the DRENDA work flow is processed once
and not according to the cross validation scheme, due
to processing time.
Evaluation measures
In order to evaluate the correctness of the results
derived from the co-occurrence based entity recognition
(Figure 1, Result set co-occurrence) and the entity
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titles) steps in the DRENDA work flow some commonly
used measures, including precision, recall, accuracy, spe-
cificity, F1 score and Matthews correlation coefficient
(MCC), were calculated based on the test sets formed
from the manually annotated corpus (Figure 1, Test
corpus). The correct estimated presence of an enzyme
and disease entity in the co-occurrence is counted as a
true positive (tp), the correct estimated absence of one
or both is counted as true negative (tn). If there are no
co-occurring enzyme or disease entities or even one
entity is missing but erroneously denoted as co-occur-
ring it is considered as a false positive (fp) prospect.
The case of co-occurring entities present which are not
found by the routine is considered as false negative (fn).
In the classification the correct assignment of a sen-
tence to one of the classification categories is assessed
as tp. The incorrect assignment to a classification cate-
gory is assessed as fp. The correct neglected assignment
to a classification category is assessed as tn and the
incorrect neglected assignment as fn. The evaluation
measures are defined as:
Precision =
tp
tp + fp
(3)
Recall = truepositiverate =
tp
tp + fn
(4)
falsepositiverate =
fp
fp + tn
(5)
Accuracy =
tp + tn
tp + tn + fp + fn
(6)
Speciﬁcity = truenegativerate =
tn
fp + tn
(7)
F1score =2·
Precision · Recall
Precision + Recall
(8)
MCC =
tp × tn − fp × fn

tp + fn

tp + fp

tn + fp

tn + fn
 (9)
In the five-fold cross-validation the values are also
accompanied by the standard deviation.
In order to evaluate the benefit of a threshold varia-
tion to the predictive performance of the classification
models receiver operating characteristic (ROC) curves
have been plotted for the results of the five-fold cross-
validation. In these ROC curves the average recall, or
true positive rate, was plotted versus the false positive
rate. The ROC plots and the calculation of the area
under the curve (AUC) were performed by the use of
the R package ROCR [23].
Results and Discussion
Enzyme and Disease related references
The content of DRENDA focuses on information on
enzymes and ignores other proteins which may also be
of biomedical relevance in a physiological and pathophy-
siological context. This selection is caused by the avail-
able extended dictionaries of enzyme names and on the
close relationship of DRENDA as a text mining derived
knowledge source which contributes to the expert anno-
tated information of BRENDA [7].
Altogether 522,720 distinct references (table 1) were
retrieved containing one or more co-occurring enzyme
and disease. Within these references 4,061 different dis-
eases are identified and assigned to 1,979 different EC
numbers which leads to 112,805 distinct EC numbers/
disease combinations. Then u m b e ro fD R E N D Ae n t r i e s
varies between enzyme classes (table 1). The hydrolases
(EC class 3) are more frequently associated with patho-
logical conditions and represent almost 50% of the
DRENDA entries.
Notably peptidases (EC sub-class 3.4.) catalysing the
cleavage of peptides and proteins form 53% of the
DRENDA entries of hydrolases. They are the EC sub-
class with the highest quantity of distinct EC numbers,
containing with 41% a remarkable part of all hydro-
lases classified so far. Peptidases perform many essen-
tial functions within eukaryotic life e.g. in the blood
coagulation cascade (thrombin, plasmin), the immuno-
logic complement system (complement protease C1r,
complement factor D), digestion of food proteins (pep-
sin, trypsin). Thus a deficiency of a peptidase may lead
to manifold pathological processes. Their full function-
ality e.g. as virulence factors in bacteria (anthrax lethal
factor endopeptidase) is also of pathogenic importance.
In BRENDA about 20% of the inhibitor-related entries
are connected to peptidases. This increased emergence
indicates a high research interest especially in the
medical field. Inhibition of a proteolytic enzyme is
often a part of a potential therapeutic strategy. In com-
parison, other enzyme classes are not as strongly
represented. The ligases (EC class 6) are rather infre-
quently connected to diseases (table 1). In BRENDA
only 3% of the inhibitor-related entries are connected
to ligases.
The results of the co-occurrence based disease and
enzyme entity recognition were compared to the corre-
sponding annotations of the test/train corpus. The co-
occurrence related F1 score is up to 88.8% and shows
an accuracy of 89.8%. The large collection of enzyme
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and a disadvantage. Homonyms are one form of ambi-
guity. These are words that share the same spelling
but have different meanings. They may lead to false
positive matches. This originates from the use of gen-
eral terms for enzymes, like the use of “lethal toxin”
for anthrax lethal factor endopeptidase (EC 3.4.24.83),
an enzyme that catalyses the hydrolysis of mitogen-
activated protein kinase kinases and is secreted by
virulent strains of the bacterium Bacillus anthracis as
an enzymatic part of its exotoxin. Short acronyms in
particular tend to be homonyms like “AAA”,o n eo f
the synonyms for aryl-acylamidase (EC 3.5.1.13).
“AAA” can have diverse meanings in a (bio-) medical
article e.g. abdominal aortic aneurysm or American
Ambulance Association. Where possible the diction-
aries are optimized with respect to a deletion of homo-
nyms and any ambiguous terms. The deletion of terms
has to be considered with care because ignoring this
terms also leads to a certain amount of missed entities
(false negative) and thus the recall value decreases.
Moreover there are other pitfalls in bio-entity recogni-
tion. There is a tendency in the literature to create
new terms for enzyme disregarding the established sys-
tematic nomenclature. This increases the effort to keep
dictionaries up-to-date with all used synonyms. Spel-
ling mistakes also increase the difficulty in identifying
entities.
Classification performance check
The classification feature included in DRENDA was
tested in a five-fold cross-validation. The F1 score for
classification ranges between 0.802 ± 0.032 and 0.738
± 0.033 (0.583 ± 0.076 and 0.395 ± 0.058 correspond-
ing MCC) depending on the category and pre-proces-
sing procedures (table 2). One of the eminent
observations of the cross-validation results is the rather
small influence of the preprocessing methods of
removal (table 2, a) and replacement (table 2, b) of
terms representing the entities “enzyme” and “disease”
on the F1 score and the AUC values (table 2) of the
ROC plots in Figure 2.
The category with the best F1 score is therapeutic
application with 0.802 ± 0.032 for the removal prepro-
cessing and 0.792 ± 0.016 for replacement preproces-
sing. This category shows also the maximum AUC
values (0.878 ± 0.040 removal, 0.878 ± 0.038 replace-
ment) and the maximum MCCs (0.583 ± 0.076 removal,
0.548 ± 0.041 replacement). The F1 scores of the cate-
gories causal interaction and ongoing research are
comparable.
However, with an F1 score of 0.744 ± 0.020 and an
MCC of 0.427 ± 0.051 for the replacement preproces-
sing, this method is more successful for the category
ongoing research than the removal preprocessing (F1
score of 0.733 ± 0.024, and an MCC of 0.395 ± 0.058.
In all other categories the removal of the terms
Table 1 A survey of the distribution of the co-occurrence derived results
Enzyme class
(EC) name
EC Diseases found
with enzyme
relation
EC numbers
found with
disease relation
Distinct combination
of EC number and
disease (a)
Distinct combination of
EC number, disease and
reference
Overall EC
numbers in
BRENDA (b)
Representation
Quotient a/b
Oxidoreductases 1 2,646 429 23,214 159,215 1,393 0.76
Transferases 2 2,862 506 23,939 283,794 1,369 0.78
Hydrolases 3 3,439 737 55,036 406,831 1,523 1.64
Lyases 4 1,721 169 6,053 31,487 494 0.56
Isomerases 5 1,350 64 3,531 22,230 186 0.86
Ligases 6 712 74 1,578 7,340 161 0.45
1-
6
4,061 1,979 112,805 910,897 5,126
a/b: The quotient of the combination of EC number and disease (a) and the overall EC numbers in BRENDA (b).
Table 2 Maximal F1 scores achieved for the classification categories and the different preprocessing methods
Category Preprocessing mode F1 score MCC AUC
therapeutic application a 0.802 ± 0.032 0.583 ± 0.076 0.878 ± 0.040
ongoing research a 0.733 ± 0.024 0.395 ± 0.058 0.752 ± 0.037
diagnostic usage a 0.738 ± 0.032 0.430 ± 0.074 0.784 ± 0.032
causal interaction a 0.743 ± 0.009 0.429 ± 0.023 0.788 ± 0.020
therapeutic application b 0.792 ± 0.016 0.548 ± 0.041 0.878 ± 0.038
ongoing research b 0.744 ± 0.020 0.427 ± 0.051 0.752 ± 0.037
diagnostic usage b 0.732 ± 0.022 0.412 ± 0.075 0.783 ± 0.033
causal interaction b 0.742 ± 0.010 0.428 ± 0.024 0.786 ± 0.020
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Page 6 of 13Figure 2 Receiver operating characteristic (ROC) plots of the models, which achieved the maximal F1 scores. The ROC plots shown
belong to the models, which achieved the maximal F1 scores (table 2) in the five-fold cross-validation with either a removal (a) or replacement
(b) preprocessing applied before the calculation of term weights. The ROC curves are vertical averaged (fixed false positive rates and averages of
the corresponding true positive rates of each turn of the five-fold cross validation). In spite of decreasing standard deviation for larger numbers
of available training sentences, the largest area under the curve (AUC) is achieved by classifiers for the category therapeutic application, which
has least annotated sentences in the test/training corpus. See table 2 for the corresponding scalar AUC values of each plot.
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achieved slightly better or equal results compared to the
replacement.
In the five-fold cross-validation two preprocessing
methods and 2,688 distinct parameter combinations
were evaluated. Results for the models with the maximal
achieved F1 scores, their corresponding Matthews Cor-
relation Coefficient (MCC) and the area under the curve
(AUC) of their receiver operating characteristic (ROC)
plots shown in Figure 2. In the removal method (a) all
terms representing the entities “enzyme” and “disease”
were removed before the calculation of term weights, in
the replacement method (b) these terms were replaced
by a general term standing for all enzyme respectively
disease terms.
As t o pw o r dremoval with different combinations of
high-frequency stop words was tested, but lowered the
quality of the classification results (data not shown) so
that it was decided not to remove stop words at all,
apart from the described removal of terms representing
enzyme and disease entities.
A word stemming stage was not included. This saves
calculation time especially for processing a large corpus
which is the result of the search for co-occurring
enzyme and disease entities. Despite the omission of a
word stemming processing step we achieve acceptable
results regarding quality and quantity and could not
observe any fatal influence on classification results.
Interrelations of enzyme disease combinations
All sentences where an enzyme and a disease entity had
been identified by the co-occurrence matching are classi-
fied by an SVM. The text corpus, consisting of the sen-
tences and titles of the co-occurrence results (Figure 1,
Result set co-occurrence), was preprocessed according to
both methods removal and replacement of entity terms.
For the classification of the co-occurrence corpus a
reduced variation of the 57 best parameters of the 5-fold
cross validation have been chosen. That comprises all para-
meter sets where a precision of at least 0.7 and an F1 score
of at least 0.5 in one or more classification category. Each
reference is assigned to one or more of the predefined
enzyme and disease relation categories causal interaction,
therapeutic application, diagnostic usage and ongoing
research. The classification decision is accomplished by a
binary SVM classification of each sentence or title. A refer-
ence can be assigned to none, one or more categories.
The classification results of the 910,897 distinct EC
number/disease/reference combinations found by the co-
occurrence matching are listed in table 3, table 4, table 5
and table 6 together with their quality parameters. The
DRENDA classification result is distributed in four confi-
dence levels. Higher confidence levels are characterized
by higher precision but lower recall. As DRENDA is part
of the BRENDA enzyme information system a high-qual-
ity result set is absolutely essential. For confidence level 4
the specificity is at least 96.7% or more and the precision
is between 97.6% and 85.5% in all categories.
Table 3 shows that 200,137 of the 910,897 combina-
tions are assigned to the category causal interaction
with a specificity of 96.7% in confidence level 4.
For each confidence level the number of matches in the
category causal interaction is higher than in the other
three categories (table 3, table 4, table 5 and table 6). A
detailed view on the overlap of the four categories is
given in Figure 3. A large subset of the categories thera-
peutic application, diagnostic usage and ongoing research
overlaps with the set causal interaction.T h r o u g h o u ta l l
four confidence levels about 50% of the results assigned
to the particular category therapeutic application, diag-
nostic usage or ongoing research (Figure 3b-d) are also
members of the category causal interaction (Figure 3).
This, of course, is expected as the fact that an enzyme
causes a disease implies, that it often can be used in
diagnosis or for therapy. For example the Gaucher’s dis-
ease, a lysosomal storage disease which is caused by a
hereditary deficiency of the enzyme glucosylceramidase
(EC 3.2.1.45), is treated by a lifelong enzyme replace-
ment therapy [24] and thus the enzyme is also the ther-
apeutic agent. However, the proportion of entries
belonging to all four categories decreases strongly with
increasing confidence level. The selection in the higher
confidence levels tends to prefer unequivocal statements
and more ambiguous statements are rejected which
reduces the number of entries intersecting all categories.
Prostaglandin-endoperoxide synthase and its multiple
relevance
Prostaglandin-endoperoxide synthase (EC 1.14.99.1), one
of the most frequently retrieved enzymes, is registered
Table 3 Results and quality estimate of the category causal interaction
DRENDA confidence level Distinct combination of EC number,
disease and reference
Precision Recall Accuracy Specificity MCC
4 200,137 0.855 0.192 0.580 0.967 0.252
3 473,517 0.778 0.533 0.690 0.848 0.401
2 480,782 0.779 0.536 0.692 0.848 0.404
1 648,545 0.702 0.775 0.723 0.670 0.448
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lyses the initial step in the formation of prostaglandins,
being the central enzyme in the biosynthetic pathway
from arachidonic acid to prostaglandins.
The tissue distribution and physiological functions are
depending on the isoform of prostaglandin-endoperox-
ide synthase. It is involved in platelet aggregation, gas-
tric mucosa protection and renal electrolyte homeostasis
[25], the inducible isoenzyme of prostaglandin-endoper-
oxide synthase is involved in inflammation processes
and mitogenesis. It is expressed in response to stimuli
like cytokines, growth factors, or hormones. Further-
more, the overexpression of the inducible isoenzyme is
observed in pre-malignant and malignant neoplasms of
the colon, liver, pancreas, breast, lung, bladder, skin, sto-
mach, head and neck [26]. Prostaglandin-endoperoxi-
dase synthase is a target of nonsteroidal anti-
inflammatory drugs like Ibuprofen and Acetylsalicylic
acid and is relevant in the treatment of mild to moder-
ate pain, fever, inflammation processes and cardiovascu-
lar and rheumatic diseases. Hence it is not surprising
that in each DRENDA confidence level it is one of the
enzymes which ranges throughout in the top ten in the
intersection set of all four classification categories.
Part of the training/test corpus was manually reanno-
tated by a second expert with a background in biochem-
istry and enzymology in order to determine the inter-
curator agreement. Reannotation was performed without
knowledge of the annotation of the first curator (biome-
dical background). The amount of the inter-curator
agreement ranged between 89.6% (therapeutic applica-
tion)a n d6 6 . 0 %( ongoing research) with most of the dif-
ferences occurring in the between ongoing research
classification and one of the others. In many cases the
difference occurred in the assessment whether statement
made by the authors is strong enough to put it into one
of the defined categories causal interactions, diagnostic
or therapeutic or whether it is additional research is
needed.
Comparison with DrugBank
The DrugBank [27] database supplies information on
drugs and their related drug targets. We compared our
results of the category therapeutic application with the
entries of DrugBank version 2.5. The 39,023 entries for
drug targets in DrugBank consist of 9,713 distinct terms
of which 1,187 could be identified as an enzyme entity
and associated with an EC number. From the DrugBank
text entry indications we could identify 264 disease enti-
ties representing about 6% of the distinct disease entities
included in DRENDA. A comparison showed that
between 72.8% and 76.4% of the combinations of EC
number, disease and PubMed reference in DRENDA are
confirmed by DrugBank (table 7), depending on the
confidence level.
Accession to DRENDA
The DRENDA disease and enzyme related data are
available via the BRENDA web portal http://www.
brenda-enzymes.org in the section “Disease/Diagnostics”
( F i g u r e4 ) .T h eD R E N D Ad a t aa r ef u l l ys e a r c h a b l ev i aa
query form (Figure 5a). The fields provided allow
searching a full or partial name of a disease, an enzyme,
an EC number or the title of a publication. These fields
can individually be combined for an optimal refinement
of the query. By the selection of the check boxes of the
fields “Category” or “Confidence Level” the classification
results of the retrieved references are visible. By submit-
ting the query a result table is created, according to the
requested information (Figure 5b). Every entry contains
links to the BRENDA flat file view of the enzyme, a
search for amino acid sequences of the enzyme, a view
on the catalysed reaction and a link to the abstract of
the reference to PubMed. Thus DRENDA results are
Table 4 Results and quality estimate of the category ongoing research
DRENDA confidence level Distinct combination of EC number,
disease and reference
Precision Recall Accuracy Specificity MCC
4 68,596 0.889 0.137 0.560 0.983 0.225
3 313,954 0.744 0.547 0.680 0.812 0.372
2 356,341 0.740 0.607 0.697 0.786 0.400
1 580,170 0.642 0.812 0.680 0.547 0.372
Table 5 Results and quality estimate of the category therapeutic application
DRENDA confidence level Distinct combination of EC number,
disease and reference
Precision Recall Accuracy Specificity MCC
4 158,143 0.976 0.548 0.767 0.986 0.594
3 182,532 0.938 0.616 0.788 0.959 0.612
2 345,421 0.855 0.808 0.836 0.863 0.672
1 422,601 0.831 0.877 0.849 0.822 0.700
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Page 9 of 13effectively connected to gain close information about the
enzyme from the BRENDA information system.
Conclusions
DRENDA provides broad information on enzymes and
diseases arranged according to EC number and disease
name. A first version of DRENDA is accessible via the
BRENDA web portal http://www.brenda-enzymes.org.
The DRENDA information collection contains the co-
occurrence based enzyme/disease entries and the
accession to the additional information on the type of
relation of the enzyme and the disease. The statements
and conclusions within a reference on the relation of an
enzyme and a disease are assigned to the categories cau-
sal interaction, ongoing research, therapeutic application
and diagnostic usage. The DRENDA content is biannu-
ally updated in the course of a new BRENDA release.
Thus DRENDA covers interesting biomedical aspects
like the pharmacological or diagnostic value of an
enzyme in connection to a disease.
Table 6 Results and quality estimate of the category diagnostic usage
DRENDA confidence level Distinct combination of EC number,
disease and reference
Precision Recall Accuracy Specificity MCC
4 193,632 0.939 0.326 0.653 0.979 0.403
3 354,083 0.833 0.632 0.753 0.874 0.521
2 401,714 0.795 0.695 0.758 0.821 0.520
1 454,540 0.764 0.716 0.747 0.779 0.496
Figure 3 The quota of intersection of classification categories (numbers × 10
3, rounded). The overall amount of distinct EC, disease and
PubMed reference combinations in the categories causal interaction (grey), therapeutic application (blue), ongoing research (pink) and diagnostic
usage (green) in every DRENDA confidence level 1-4. The number of unassigned combinations is listed in the sets (yellow) at the bottom of
each plot.
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Page 10 of 13Table 7 The DrugBank entries for drug targets in comparison with the entries of DRENDA
DRENDA
confidence
level
EC numbers
in DRENDA
DRENDA/
DrugBank
agreement
EC number, disease and
PubMed reference combination
DRENDA/
DrugBank
agreement
DRENDA/DrugBank agreement
with consideration of diseases
1 1,622 863 (53.2%) 422,601 307,477 (72.8%) 18,834 (4.5%)
2 1,516 831 (54.8%) 345,421 251,460 (72.8%) 17,018 (4.9%)
3 1,227 710 (57.9%) 182,532 137,701 (75.4%) 12,466 (6.8%)
4 1,183 694 (58.7%) 158,143 120,760 (76.4%) 11,448 (7.2%)
The entries of DRENDA which have are assigned to the category therapeutic application put in relation to DrugBank entries. The amount of EC numbers and
combinations of EC number, disease and PubMed reference are listed together with the quantity of coinciding DrugBank entries for drug target enzymes with
and without consideration of matching disease.
Figure 4 Screen shot of the BRENDA web portal entry with a view on the DRENDA query form.
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